截至2026年2月25日收盘，*ST景峰(000908)报收于6.52元，下跌1.66%，换手率1.9%，成交量16.7万手， 成交额1.09亿元。 2026年2月3日，湖南景峰医药股份有限公司收到湖南省常德市中级人民法院裁定，批准公司重整计划并 终止重整程序，公司进入重整计划执行阶段。根据重整计划，公司以现有总股本879,774,351股为基数， 按每10股转增10股实施资本公积金转增股本，转增后总股本将增至1,759,548,702股。转增股份不向原股 东分配，全部由重整投资人现金受让，用于支付破产费用、清偿债务及补充流动资金。若股权登记日收 盘价高于2.34元/股，股价可能存在向下除权调整风险。公司提醒投资者注意投资风险。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：2月25日主力资金净流出1161.3万元，显示大额资金呈离场态势。 来自公司公告汇总：公司重整计划获批，资本公积金转增股本后总股本将增至1,759,548,702股， 存在股价向下除权风险。 交易信息汇总资金流向 2月25日主力资金净流出11 ...

Group 1 - The stock price of *ST Asia Pacific (000691) closed at 9.1 yuan on December 30, 2025, down 3.6%, with a turnover rate of 5.5% and a trading volume of 177,900 hands, resulting in a transaction amount of 164 million yuan [1] - On December 30, 2025, the net outflow of main funds was 14.93 million yuan, while retail investors saw a net inflow of 9.71 million yuan [3] - The company has entered the execution phase of its restructuring plan, approved by the Gansu Provincial Intermediate People's Court on December 26, 2025, which includes a capital reserve increase of 50% (5 shares for every 10 shares) [1][3] Group 2 - The company will suspend trading for one day on December 31, 2025, due to the implementation of the capital reserve increase, with the stock resuming trading on January 5, 2026 [1][3] - The total share capital will increase from 323,270,000 shares to 484,905,000 shares following the capital reserve increase, with all new shares allocated to attract restructuring investors [1] - If the restructuring plan is not executed or cannot be executed, the company faces the risk of bankruptcy declaration and stock delisting [1][3]

Core Viewpoint - The stock of Ningxia Zhongke Biotechnology Co., Ltd. (*ST Ningke) has experienced a strong performance with a consecutive seven-day limit-up, closing at 3.99 yuan per share, despite the company issuing multiple risk warning announcements [1][3]. Group 1: Stock Performance - As of December 19, *ST Ningke's stock price reached 3.99 yuan per share, marking a 5.00% increase [2]. - The stock has shown a significant upward trend, with moving averages indicating a rise: MA5 at 3.63, MA10 at 3.27, MA20 at 3.02, and MA60 at 2.81 [2]. Group 2: Risk Warnings - The company has issued several risk warnings, stating that there have been no significant changes in its fundamentals and no undisclosed major information [3]. - Key risks highlighted include the court's decision to terminate the restructuring process, which could lead to bankruptcy if the restructuring plan is not executed [3][4]. Group 3: Corporate Changes - The company recently completed a change in its controlling shareholder, with Hunan Xinhai New Biological Medicine Co., Ltd. becoming the new controlling shareholder, holding 22.10% of the total shares [4]. - The restructuring plan involved transferring 8.83 billion shares to restructuring investors, representing 54.64% of the total shares [4]. Group 4: Financial Performance - Financial data shows that *ST Ningke has reported negative net profits for three consecutive years, with a net profit of -539 million yuan for 2024 and -251 million yuan for Q3 2025 [5]. - The company has faced administrative penalties from the China Securities Regulatory Commission for violations, leading to additional risk warnings on its stock [5]. Group 5: Market Sentiment - Analysts express that the recent stock price surge may be driven more by market speculation rather than improvements in the company's fundamentals [7]. - Despite the restructuring providing potential opportunities, the company still faces significant operational pressures and financial risks [7].

Core Viewpoint - *ST Dongyi's stock has experienced significant volatility, with a price increase of 241.59% since September 26, 2025, leading to a suspension of trading for further investigation [2][4]. Group 1: Stock Performance - Since September 29, 2025, *ST Dongyi has recorded 23 limit-up days and 1 limit-down day within 28 trading days, with a cumulative increase exceeding 240% [4]. - The stock has experienced 9 instances of abnormal fluctuations between October 10 and November 13, 2025, indicating a serious deviation from the company's fundamentals [2]. Group 2: Financial Metrics - As of November 12, 2025, the company's static P/E ratio is -6.03, rolling P/E ratio is -10.88, and P/B ratio is -6.06, which are significantly lower than the industry averages of 26.83 for static P/E, 23.94 for rolling P/E, and 2.34 for P/B [6]. Group 3: Restructuring Situation - The company is undergoing a pre-restructuring process initiated by the Beijing First Intermediate People's Court, with no formal acceptance of the restructuring application received yet [6]. - If the court accepts the restructuring application, the stock will face "delisting risk warning," and failure to complete the restructuring by December 31, 2025, could lead to bankruptcy and delisting [6].